Refining docetaxel-containing therapy for gastric cancer

Gastrointestinal Cancer Research

Volumn 4, Issue 3, 2011, Pages 96-105

  Khokhar, Nushmia Z ^a   Jiang, Yixing ^b   Benson III, Al B ^a   Ajani, Jaffer A ^c   Mulcahy, Mary F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PLATINUM COMPLEX; SORAFENIB;

ABDOMINAL PAIN; ACNE; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPONATREMIA; INFECTION; LETHARGY; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAINTENANCE DRUG DOSE; MAXIMUM TOLERATED DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; RASH; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH HEMORRHAGE; STOMACH PERFORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 80052984486     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Globocan 2002. Available at: http://www-dep.iarc.fr/. Accessed 20 June 2009).
2. The National Cancer Institute. Available at: http://www.cancer.gov/cancertopics/types/stomach/. Accessed 20 June 2009
3. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI). Available at: http://seer.cancer.gov/statfacts/html/stomach.html. Accessed 20 June 2009
4. Crew KD, Neugut AI: Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31:450-464, 2004
5. Gee DW, Rattner DW: Management of gastroesophageal tumors. Oncologist 12:175-185, 2007
6. Pyrhonen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995
7. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
8. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168, 1997
9. Kim NK, Park YS, Heo DS, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818, 1993
10. Tebbutt NC, Norman A, Cunningham D, et al: A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 13:1568-1575, 2002
11. Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-59, 2003
12. Mavroudis D, Kourousis C, Androulakis N, et al: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 23:341-344, 2000
13. Graziano F, Catalano V, Baldelli AM, et al: A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11:1263-1266, 2000
14. Einzig AI, Neuberg D, Remick SC, et al: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13:87-93, 1996
15. Bang YJ, Kang WK, Kang YK, et al: Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 32:248-254, 2002
16. Mai M, Sakata Y, Kanamaru R, et al: [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)]. Gan To Kagaku Ryoho 26:487-496, 1999 [Japanese]
17. Maeda S, Saikawa Y, Kubota T, et al: No crossresistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay. Anticancer Res 23:3147-3150, 2003
18. Maeda S, Sugiura T, Saikawa Y, et al: Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 5:679-684, 2004
19. Kodera Y, Fujiwara M, Yokoyama H, et al: Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts. In Vivo 19:861-866, 2005
20. Deeks ED, Scott LJ: Docetaxel: in gastric cancer. Drugs 67:1893-1901, 2007
21. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006
22. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3210-3216, 2007
23. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3205-3209, 2007
24. Gridelli C, Gallo C, Di Maio M, et al: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91:1996-2004, 2004
25. Tabernero J, Climent MA, Lluch A, et al: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365, 2004
26. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
27. Hejna M, Raderer M, Zacherl J, et al: Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS. 1.2.001. Anticancer Drugs 19:535-539, 2008
28. Kim JG, Sohn SK, Chae YS, et al: Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer 98:542-546, 2008
29. Park Y, Kim K, Choi M, et al: A phase I/II trial of docetaxel (D) and oxaliplatin (O) in patients with advanced gastric cancer (AGC). 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 26, 15S (May 20 suppl), 2008 (abstr 15615)
30. Richards D, McCollum D, Wilfong L, et al: Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol 19:104-108, 2008
31. Quintero G, Jorge M, Casal J, et al: Phase II study of biweekly docetaxel and cisplatin combination chemotherapy in first-line advanced gastric cancer. J Clin Oncol 26, 2008 (abstr 15601a)
32. Kim J, Song H, Do Y, et al: A multicenter phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 26, 15S (May 20 suppl), 2008 (abstr 15520)
33. Park KW, Ahn JS, Park YS, et al: Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol 59:17-21, 2007
34. Sym S, Park S, Kwon K, et al: A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: preliminary results. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, January 15-17, 2009 (abstr 92a)
35. Shankaran V, Mulcahy MF, Hochster HS, et al: Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, January 15-17, 2009 (abstr 47a)
36. Wang B, Zhang W, Hong X, et al: Phase I dose-escalating study of 24-h continuous infu-sion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol 63:213-218, 2009
37. Ho L, Phan AT, Jhamb J, et al: Retrospective review of docetaxel, cisplatin, and 5-FU (DCF) given on a weekly basis for the treatment of advanced gastric or esophageal cancer. J Clin Oncol 26, 2008 (abstr 15525a)
38. Kazmi SM, Jhamb J, Joseph M, et al: Toxicity and efficacy of a weekly-based docetaxel, cisplatin, and 5-FU (DCF) as first-line treatment for advanced gastric and esophageal cancer. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, January 15-17, 2009 (abstr 68a)
39. Lorenzen S, Hentrich M, Haberl C, et al: Splitdose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18:, 1673-16792007
40. Reza MS, Hai MA, Chowdhury Q: A phase II trial of docetaxel, cisplatin plus 5-fluorouracil (DCF) as first-line therapy in patients with metastatic or locally advanced inoperable gastric adenocarcinoma. J Clin Oncol 26, 2008 (abstr 15620a)
41. Roth AD, Fazio N, Stupp R, et al: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217-3223, 2007
42. Power DG, Wu N, Qin W, et al: Docetaxel clearance and cisplatin administration: implications for toxicity of docetaxel, cisplatin, and fluorouracil (DCF) in gastric cancer. J Clin Oncol 26, 2008 (abstr 13502a)
43. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
44. Evans D, Miner T, Akerman P, et al: A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol 30:346-349, 2007
45. Schonneman KR, Andersen M, Yilmaz M, et al: Phase I study of docetaxel, oxaliplatin, and capecitabine as first line therapy to patients with advanced gastro-esophageal cancer. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, January 15-17, 2009 (abstr 71a)
46. Sym S, Ryu M, Lee J et al: Phase I study of docetaxel, capeciabine and oxaliplatin (DXO) combination chemotherapy as a first-line treatment in patients with advanced gastric cancer. ASCO Gastrointestinal Cancers Symposium, Orlando, FL, USA, January 25-27, 2008 (abstr 122a)
47. Aggarwal S, Goel G, Jauhri M, et al: Efficacy of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastroesophageal cancers. Ann Oncol 19, 2008 (abstr 562a)
48. Koizumi W, Kurihara M, Nakano S, et al: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191-197, 2000
49. Sakata Y, Ohtsu A, Horikoshi N, et al: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720, 1998
50. Kunisaki C, Takahashi M, Nagahori Y, et al: Phase I study of biweekly docetaxel and S-1 combination chemotherapy for advanced gastric cancer. Anticancer Res 28:2473-2478, 2008
51. Park SR, Kim HK, Kim CG, et al: Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer 98:1305-1311, 2008
52. Sato Y, Takayama T, Sagawa T, et al: Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. J Clin Oncol 26, 2008 (abstr 4537a)
53. Yamaguchi K, Shimamura T, Hyodo I, et al: Phase I/II study of docetaxel and S1 in patients with advanced gastric cancer. Br J Cancer 94:1803-1808, 2006
54. Yoshida K, Ninomiya M, Norihisa T, et al: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402-3407, 2006
55. Nakayama N, Koizumi W, Sasaki T, et al: A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 75:1-7, 2008
56. Jeung H, Im C, Rha S, et al: A randomized phase II trial of docetaxel plus S-1 versus docetaxel plus cisplatin in advanced gastric cancer as first-line treatment. J Clin Oncol 26, 2008 (abstr 4534a)
57. Yoshida K, Yamaguchi K, Osada S, et al: Challenge for a better combination with basic evidence. Int J Clin Oncol 13:212-219, 2008
58. Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26:2118-2123, 2008
59. Koizumi W, Tanabe S, Saigenji K, et al: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207-2212, 2003
60. Ajani JA, Faust J, Ikeda K, et al: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23:6957-6965, 2005
61. Daigo S, Takahashi Y, Fujieda M, et al: A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype toward tegafur. Pharmacogenetics 12:299-306, 2002
62. Dende T, Sudo K, Nakamura K, et al: Biweekly combination chemotherapy of docetaxel, irinotecan and cisplatin as second-line treatment for advanced gastric cancer. Ann Oncol 19, 2008 (abstr 533a)
63. Di Lauro L, Nunziata C, Arena MG, et al: Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 97:593-597, 2007
64. Di Lauro L, Giacinti L, Arena MG, et al: Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: a phase II study. J Clin Oncol 26, 2008 (abstr 15512a)
65. El-Rayes BF, Hammad N, Philip PA, et al: A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer. J Clin Oncol 26, 2008 (abstr 15608a)
66. Enzinger P, Fidias P Meyerhardt J et al: Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, January 24-26
67. Enzinger PF, Regan E, Lehman T, et al: Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Ann Oncol 19(Suppl. 8):viii171-viii172, 2008
68. Jhawer M, Tse A, Ilson D, et al: Phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, January 15-17, 2009 (abstr 10a)
69. Ohtsu A: Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 43:256-264, 2008
70. Sun W, Powell ME, O'Dwyer PJ, et al: A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). J Clin Oncol 28;2947-2951, 2010
71. Pinto C, Di Fabio F, Siena S, et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510-517, 2007
72. Lordick F, Lorenzen S, Hegewisch-Becker S, et al: Cetuximab plus weekly oxaliplatin/5-FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. J Clin Oncol 25, 2007 (abstr 4526)
73. Pinto C, Di Fabio F, Barone C, et al: Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study). J Clin Oncol 26, 2008 (abstr 4575a)
74. Tebbutt NC, Sourjina T, Strickland AH, et al: ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer. Final results of a multicentre phase II trial by the AGITG. J Clin Oncol 26(15 Suppl):510-15554, 2008 (abstr 15554a)
75. Muro K, Boku N, Yamada Y, et al: Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results. ASCO Gastrointestinal Cancers Symposium, Orlando, FL, USA, January 25-27, 2008 (abstr 4541)
76. Bang Y, Kang Y, Kang W, et al: Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study. ASCO Gastrointestinal Cancers Symposium, Orlando, FL, USA, January 19-21, 2007 (abstr 4603)
77. Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529, 2008
78. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Available at: http//www.nccn.org/professionals/physician-_gls/f_guidelines.asp. Accessed 22 June 2009
79. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184, 2005
80. Martin M, Lluch A, Segui MA, et al: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212, 2006